| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Division of Infectious Diseases, Department of Pediatrics, Duke University Medical Center, and the Durham Veterans Administration Medical Center, Durham, NC.
2 From the Divisions of Pulmonary and Critical Care Medicine, Duke University Medical Center, and the Durham Veterans Administration Medical Center, Durham, NC.
3 From the Division of General and Thoracic Surgery, Duke University Medical Center, and the Durham Veterans Administration Medical Center, Durham, NC.
4 From the Department of Surgery, Department of Pathology, Duke University Medical Center, and the Durham Veterans Administration Medical Center, Durham, NC.
5 From the Division of Pulmonary Medicine, Department of Pediatrics, Duke University Medical Center, and the Durham Veterans Administration Medical Center, Durham, NC.
Background: There is controversy over whether colonization with drug-resistant organisms is a contraindication to lung transplantation.
Methods: We undertook a retrospective review of the results of lung transplantation for patients with cystic fibrosis (CF) at Duke University Medical Center.
Results: As of May 1996, 21 patients with CF underwent bilateral lung transplantation. The first patient died within 24 h of transplantation from sepsis due to Stenotrophomonas maltophilia. Of the remaining 20 patients, 17 (85%) are alive and in stable condition. The three deaths were related primarily to bronchiolitis obliterans at 4 and 18 months in two patients and to cytomegalovirus pneumonitis at 5 months in the other patient. The 17 surviving patients have been followed up for a mean of 13 months (range, 0.5 to 34 months). Most of them were colonized and infected with multidrug-resistant organisms before transplantation. Following transplantation, 11 patients had complications from infections. One patient had bacteremia due to a panresistant Burkholderia cepacia and was treated successfully. Two patients had bacteremia and wound infection due to Burkholderia gladioli, previously thought to be pathogenic only in plants. Both patients were treated successfully. Of the six patients with Aspergillus fumigatus isolated from cultures before transplantation, only one had invasive disease following transplantation and responded to treatment.
Conclusion: The organisms present before transplantation were not the primary cause of mortality in our patient population. Our findings suggest that lung transplantation should be considered in CF patients infected with multidrug-resistant organisms.
Key Words: cystic fibrosis • infections • lung transplantation
Submitted on January 23, 1997
Accepted on April 1, 2007
This article has been cited by other articles:
|
|
 |
|
  M. Helmi, R. B. Love, D. Welter, R. D. Cornwell, and K. C. Meyer Aspergillus Infection in Lung Transplant Recipients With Cystic Fibrosis: Risk Factors and Outcomes Comparison to Other Types of Transplant Recipients Chest, March 1, 2003; 123(3): 800 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lick and A. Duarte Of Mycetomas and Men Chest, January 1, 2002; 121(1): 5 - 6. [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. ARIS, J. C. ROUTH, J. J. LIPUMA, D. G. HEATH, and P. H. GILLIGAN Lung Transplantation for Cystic Fibrosis Patients with Burkholderia cepacia Complex . Survival Linked to Genomovar Type Am. J. Respir. Crit. Care Med., December 1, 2001; 164(11): 2102 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Mehrad, G. Paciocco, F. J. Martinez, T. Clark Ojo, M. D. Iannettoni, and J. P. Lynch III Spectrum of Aspergillus Infection in Lung Transplant Recipients : Case Series and Review of the Literature Chest, January 1, 2001; 119(1): 169 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Brisse, C. M. Verduin, D. Milatovic, A. Fluit, J. Verhoef, S. Laevens, P. Vandamme, B. Tümmler, H. A. Verbrugh, and A. van Belkum Distinguishing Species of the Burkholderia cepacia Complex and Burkholderia gladioli by Automated Ribotyping J. Clin. Microbiol., May 1, 2000; 38(5): 1876 - 1884. [Abstract] [Full Text]
|
|
|
|
|
|
L. Saiman, J. L. Burns, S. Whittier, J. Krzewinski, S. A. Marshall, and R. N. Jones Evaluation of Reference Dilution Test Methods for Antimicrobial Susceptibility Testing of Pseudomonas aeruginosa Strains Isolated from Patients with Cystic Fibrosis J. Clin. Microbiol., September 1, 1999; 37(9): 2987 - 2991. [Abstract] [Full Text]
|
|
|
|
|
|
C. van Pelt, C. M. Verduin, W. H. F. Goessens, M. C. Vos, B. Tümmler, C. Segonds, F. Reubsaet, H. Verbrugh, and A. van Belkum Identification of Burkholderia spp. in the Clinical Microbiology Laboratory: Comparison of Conventional and Molecular Methods J. Clin. Microbiol., July 1, 1999; 37(7): 2158 - 2164. [Abstract] [Full Text]
|
|
|
|
|
|
C. Segonds, T. Heulin, N. Marty, and G. Chabanon Differentiation of Burkholderia Species by PCR-Restriction Fragment Length Polymorphism Analysis of the 16S rRNA Gene and Application to Cystic Fibrosis Isolates J. Clin. Microbiol., July 1, 1999; 37(7): 2201 - 2208. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
